Cancel anytime
NanoString Technologies Inc (NSTGQ)NSTGQ
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/25/2024: NSTGQ (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -76.71% | Upturn Advisory Performance 1 | Avg. Invested days: 14 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 06/25/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -76.71% | Avg. Invested days: 14 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 06/25/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD |
Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - |
Volume (30-day avg) 762921 | Beta - |
52 Weeks Range 0.04 - 5.18 | Updated Date 06/6/2024 |
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - | Volume (30-day avg) 762921 | Beta - |
52 Weeks Range 0.04 - 5.18 | Updated Date 06/6/2024 |
Earnings Date
Report Date 2024-06-21 | When AfterMarket |
Estimate -1.24 | Actual - |
Report Date 2024-06-21 | When AfterMarket | Estimate -1.24 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - |
Shares Outstanding - | Shares Floating - |
Percent Insiders - | Percent Institutions - |
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating 4 | Target Price - | Buy - |
Strong Buy 1 | Hold 1 | Sell - |
Strong Sell - |
Rating 4 | Target Price - | Buy - | Strong Buy 1 |
Hold 1 | Sell - | Strong Sell - |
AI Summarization
NanoString Technologies Inc. (NASDAQ: NSTG)
Company Profile:
NanoString Technologies is a molecular diagnostics company that develops and sells innovative platforms and consumables for life science research and clinical diagnostics. The company's primary technology is the nCounter® Analysis System, a digital spatial profiling platform for analyzing gene expression and protein levels in single cells and tissues.
Top Products and Market Share:
- nCounter Analysis System: This is NanoString's flagship product and holds a leading position in the spatial transcriptomics market. Its market share is estimated to be around 25% in this rapidly growing segment.
- GeoMx® Digital Spatial Profiler (DSP): This platform enables researchers to perform spatial profiling at higher resolution and with increased multiplexing capabilities. It is a relatively new offering, and its market share is still developing.
- CosMx Spatial Molecular Imager (SMI): This platform is specifically designed for clinical research and diagnostics. It is gaining traction in the field of precision oncology, where spatial profiling plays a crucial role in understanding tumor heterogeneity.
Financial Performance:
NanoString's revenue has grown steadily over the past few years, driven by the increasing adoption of its nCounter platform and the launch of new products like GeoMx and CosMx. The company reported revenue of $112.3 million in 2022, an increase of 22% year-over-year. However, NanoString is not yet profitable and continues to incur significant operating expenses related to research and development, marketing, and sales.
Growth Trajectory:
The market for spatial transcriptomics is expected to experience significant growth in the coming years, fueled by the increasing demand for personalized medicine and the need for better understanding of complex biological processes. NanoString is well-positioned to capitalize on this growth with its leading nCounter platform and expanding product portfolio.
Market Dynamics:
The spatial transcriptomics market is highly competitive, with several other companies developing similar technologies. Some of NanoString's key competitors include:
- 10X Genomics (NASDAQ: TXG) - Market share: 20-25%
- Illumina (NASDAQ: ILMN) - Market share: 15-20%
- Bio-Rad Laboratories (NYSE: BIO) - Market share: 10-15%
Potential Challenges:
- Competition: NanoString faces stiff competition from established players like Illumina and 10X Genomics with larger market share and resources.
- Reimbursement: Obtaining reimbursement for its diagnostic products from major payers remains a key challenge.
- Profitability: Reaching profitability remains elusive as research and development costs coupled with marketing expenses continue to weigh on margins.
Opportunities:
- Expanding market: The spatial transcriptomics market is projected to grow significantly, creating ample opportunities for NanoString to expand its customer base.
- New product launches: The launch of innovative products like GeoMx and CosMx opens up new avenues for growth in clinical research and diagnostics.
- Strategic partnerships: Collaborations with pharmaceutical companies and research institutions could accelerate the adoption of NanoString's technologies.
Fundamental Rating based on AI: 7.5
The AI-based rating of 7.5 reflects NanoString's strong product portfolio, leading position in a rapidly growing market, and significant growth potential. However, the company's lack of profitability and intense competition remain concerns that temper the overall rating.
Justification:
- Strengths:
- Leading technology in the spatial transcriptomics market.
- Diversifying product portfolio addressing different market segments.
- Strong revenue growth driven by increasing adoption of its platforms.
- Weaknesses:
- Still not profitable and faces pressure on margins.
- Intense competition from established players with larger resources.
- Reimbursement challenges for its diagnostic products.
Overall, NanoString Technologies Inc. is a promising company with innovative technologies and a significant growth opportunity. However, investors should be aware of the company's challenges before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NanoString Technologies Inc
Exchange | NASDAQ | Headquaters | Seattle, WA, United States |
IPO Launch date | 2013-06-26 | CEO, President & Director | Mr. R. Bradley Gray |
Sector | Healthcare | Website | https://www.nanostring.com |
Industry | Medical Instruments & Supplies | Full time employees | 550 |
Headquaters | Seattle, WA, United States | ||
CEO, President & Director | Mr. R. Bradley Gray | ||
Website | https://www.nanostring.com | ||
Website | https://www.nanostring.com | ||
Full time employees | 550 |
NS Wind Down Co., Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaborations with Lam Research Corporation and Parker Institute for Cancer Immunotherapy, Stanford Medicine, Acrobat Genomics, and Illumina Accelerator. The company was formerly known as NanoString Technologies, Inc. and changed its name to NS Wind Down Co., Inc. in May 2024. NS Wind Down Co., Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NS Wind Down Co., Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.